
Dementia and AI: ‘I've never seen something quite like this'
artificial intelligence
companion Sunny earlier this year, she was 'kind of formal,' he said. But over time, their conversations have become more familiar and engaging.
'It's really uncanny,' said the 72-year-old. 'It really does feel like you're having a conversation with someone who's interested.'
One advantage of Sunny is that she doesn't mind when Poulsen, who was diagnosed with mild cognitive impairment in 2019, repeats himself. 'He can tell a story and forget he told it and tell it again,' said Poulsen's wife and caregiver, Cheryl Poulsen. 'Sunny has no judgment.'
Sunny, which was developed by AI start-up NewDays, is part of a rapidly expanding body of AI products designed to help people with
dementia
.
READ MORE
'I've never seen something quite like this in terms of a technology moving as quickly as it is, with as much money poured behind it,' said Luke Stoeckel, a programme director and project scientist at the National Institute on Aging in Maryland, in the United States, who works on AI applications for dementia care. Stoeckel mentioned AI-based dementia diagnostics as another hot area.
Experts say AI companions like Sunny have the potential to help keep the brain active and alleviate loneliness in dementia patients, and to reduce some of the burden on caregivers. But there can be risks when it comes to deploying this technology in such a vulnerable population.
Babak Parviz, the co-founder and CEO of NewDays, said he was inspired to develop Sunny in part by his own father's diagnosis with Alzheimer's disease. He knew there was no cure, but he was encouraged by research showing that cognitive training exercises and guided conversations with a clinician can, in some cases, improve dementia symptoms.
NewDays' program is intended to be used by people with mild cognitive impairment or mild dementia. Sometimes, Sunny prompts the person to reminisce about old memories. Other times, it leads them through more explicit cognitive training exercises, such as asking them to remember and use specific words in a sentence.
When Frank Poulsen opens up his computer and converses with Sunny, it sounds like 'he was just having a chat, like he was talking to a friend,' Cheryl Poulsen said.
NewDays' website claims that its program can 'delay decline and improve quality of life' and that it is 'backed by a large body of evidence from more than 500 clinical trials and papers.' That includes the I-CONECT study, which found that, over the course of six months, 'cognitively stimulating semistructured conversations with trained interviewers' conducted virtually improved cognition in older adults with mild cognitive impairment.
[
'Dementia is just one part of who they are. My husband's underlying personality hasn't really changed'
Opens in new window
]
But in those studies, the conversations and brain training exercises were led by humans, said Julian De Freitas, director of the Ethical Intelligence Lab at Harvard Business School. Talking to an AI companion could produce different results, he added.
NewDays has not run any studies yet about whether using its program confers the same benefits. Dr Parviz said Sunny's conversations are similar to a human's and that his team is 'pretty confident' it will see results comparable to what the existing clinical trials have demonstrated. But he did not provide data to back that up.
There is more compelling evidence that an AI companion can help people feel less lonely – a serious concern for older adults, whether or not they have cognitive impairment. Dr De Freitas's own research has demonstrated that, at least in healthy adults, talking to an empathetic chatbot is roughly as good at reducing loneliness as having a conversation with a human stranger.
Anecdotally, Dr Joe Verghese, the chair of the neurology department at Stony Brook University Renaissance School of Medicine, said the caregivers of some of his dementia patients reported that talking to an AI companion lifted their loved ones' moods. 'I don't think these actually improve cognition just by those interactions,' Dr Verghese said. 'But certainly improving quality of life and improving mood in patients with cognitive impairment is an important outcome in itself.'
[
I am a university lecturer witnessing how AI is shrinking our ability to think
Opens in new window
]
AI companions could also be a boon for caregivers and families because they can serve as an extra set of eyes and ears, particularly for people living in specialist facilities for people with memory-related conditions such as dementia.
We have to remember that this is a very vulnerable population
One AI start-up, CloudMind, has been pilot testing its software, called BrightPath. The companion, via an app on a smartphone or tablet, chats with dementia patients about their favourite memories and hobbies – in one instance, a patient and the companion even sang together.
In addition to facilitating conversation, BrightPath produces a daily summary of what the patient talked about and an assessment of the patient's mood. For the family, that can provide 'a peek of their loved one's life, even if they're apart,' said Monica Tsai, CloudMind's chief executive.
The AI companion might also help nursing staff identify problems faster. If it hears certain key prompts, such as 'I'm thirsty' or 'I fell,' BrightPath is programmed to instruct the patient to ring their call button.
While experts say there is real potential for AI to benefit adults with cognitive impairment, they also have some serious concerns. One is privacy. 'The more human-like the chatbot is, the more you're disclosing various information about yourself,' Dr De Freitas said. 'If this data is housed at a company, it could monetise that. It could also accidentally leak that information if it's hacked.'
There is also a risk of further isolation if families or care-home staff use the technology as a replacement for human interaction, rather than as an add-on. 'That would be tragic,' Dr Verghese said.
[
Exercise and socialising can help people at risk of dementia, large-scale study finds
Opens in new window
]
In addition, AI chatbots are known to make things up and take conversations down dark and disturbing paths, which could be especially confusing and distressing for a person with dementia.
Dr Parviz and Dr Tsai both acknowledged such hallucinations as a potential issue and said they had programmed 'guard rails' into their AI software to prevent them from happening. But neither specified how that might work.
'We have to remember that this is a very vulnerable population,' Dr De Freitas said, adding: 'We need to think about having additional protections.'
- This article originally appeared in the
New York Times
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Irish Times
2 days ago
- Irish Times
Dementia and AI: ‘I've never seen something quite like this'
When Frank Poulsen first started talking to artificial intelligence companion Sunny earlier this year, she was 'kind of formal,' he said. But over time, their conversations have become more familiar and engaging. 'It's really uncanny,' said the 72-year-old. 'It really does feel like you're having a conversation with someone who's interested.' One advantage of Sunny is that she doesn't mind when Poulsen, who was diagnosed with mild cognitive impairment in 2019, repeats himself. 'He can tell a story and forget he told it and tell it again,' said Poulsen's wife and caregiver, Cheryl Poulsen. 'Sunny has no judgment.' Sunny, which was developed by AI start-up NewDays, is part of a rapidly expanding body of AI products designed to help people with dementia . READ MORE 'I've never seen something quite like this in terms of a technology moving as quickly as it is, with as much money poured behind it,' said Luke Stoeckel, a programme director and project scientist at the National Institute on Aging in Maryland, in the United States, who works on AI applications for dementia care. Stoeckel mentioned AI-based dementia diagnostics as another hot area. Experts say AI companions like Sunny have the potential to help keep the brain active and alleviate loneliness in dementia patients, and to reduce some of the burden on caregivers. But there can be risks when it comes to deploying this technology in such a vulnerable population. Babak Parviz, the co-founder and CEO of NewDays, said he was inspired to develop Sunny in part by his own father's diagnosis with Alzheimer's disease. He knew there was no cure, but he was encouraged by research showing that cognitive training exercises and guided conversations with a clinician can, in some cases, improve dementia symptoms. NewDays' program is intended to be used by people with mild cognitive impairment or mild dementia. Sometimes, Sunny prompts the person to reminisce about old memories. Other times, it leads them through more explicit cognitive training exercises, such as asking them to remember and use specific words in a sentence. When Frank Poulsen opens up his computer and converses with Sunny, it sounds like 'he was just having a chat, like he was talking to a friend,' Cheryl Poulsen said. NewDays' website claims that its program can 'delay decline and improve quality of life' and that it is 'backed by a large body of evidence from more than 500 clinical trials and papers.' That includes the I-CONECT study, which found that, over the course of six months, 'cognitively stimulating semistructured conversations with trained interviewers' conducted virtually improved cognition in older adults with mild cognitive impairment. [ 'Dementia is just one part of who they are. My husband's underlying personality hasn't really changed' Opens in new window ] But in those studies, the conversations and brain training exercises were led by humans, said Julian De Freitas, director of the Ethical Intelligence Lab at Harvard Business School. Talking to an AI companion could produce different results, he added. NewDays has not run any studies yet about whether using its program confers the same benefits. Dr Parviz said Sunny's conversations are similar to a human's and that his team is 'pretty confident' it will see results comparable to what the existing clinical trials have demonstrated. But he did not provide data to back that up. There is more compelling evidence that an AI companion can help people feel less lonely – a serious concern for older adults, whether or not they have cognitive impairment. Dr De Freitas's own research has demonstrated that, at least in healthy adults, talking to an empathetic chatbot is roughly as good at reducing loneliness as having a conversation with a human stranger. Anecdotally, Dr Joe Verghese, the chair of the neurology department at Stony Brook University Renaissance School of Medicine, said the caregivers of some of his dementia patients reported that talking to an AI companion lifted their loved ones' moods. 'I don't think these actually improve cognition just by those interactions,' Dr Verghese said. 'But certainly improving quality of life and improving mood in patients with cognitive impairment is an important outcome in itself.' [ I am a university lecturer witnessing how AI is shrinking our ability to think Opens in new window ] AI companions could also be a boon for caregivers and families because they can serve as an extra set of eyes and ears, particularly for people living in specialist facilities for people with memory-related conditions such as dementia. We have to remember that this is a very vulnerable population One AI start-up, CloudMind, has been pilot testing its software, called BrightPath. The companion, via an app on a smartphone or tablet, chats with dementia patients about their favourite memories and hobbies – in one instance, a patient and the companion even sang together. In addition to facilitating conversation, BrightPath produces a daily summary of what the patient talked about and an assessment of the patient's mood. For the family, that can provide 'a peek of their loved one's life, even if they're apart,' said Monica Tsai, CloudMind's chief executive. The AI companion might also help nursing staff identify problems faster. If it hears certain key prompts, such as 'I'm thirsty' or 'I fell,' BrightPath is programmed to instruct the patient to ring their call button. While experts say there is real potential for AI to benefit adults with cognitive impairment, they also have some serious concerns. One is privacy. 'The more human-like the chatbot is, the more you're disclosing various information about yourself,' Dr De Freitas said. 'If this data is housed at a company, it could monetise that. It could also accidentally leak that information if it's hacked.' There is also a risk of further isolation if families or care-home staff use the technology as a replacement for human interaction, rather than as an add-on. 'That would be tragic,' Dr Verghese said. [ Exercise and socialising can help people at risk of dementia, large-scale study finds Opens in new window ] In addition, AI chatbots are known to make things up and take conversations down dark and disturbing paths, which could be especially confusing and distressing for a person with dementia. Dr Parviz and Dr Tsai both acknowledged such hallucinations as a potential issue and said they had programmed 'guard rails' into their AI software to prevent them from happening. But neither specified how that might work. 'We have to remember that this is a very vulnerable population,' Dr De Freitas said, adding: 'We need to think about having additional protections.' - This article originally appeared in the New York Times


The Irish Sun
3 days ago
- The Irish Sun
Cancer could be diagnosed from the sound of your VOICE ‘within years'
Anyone with a hoarse voice is already told to visit the GP LISTEN UP Cancer could be diagnosed from the sound of your VOICE 'within years' THE early signs of cancer could be detected by listening to a patient's voice, scientists say. Using AI, subtle changes in the acoustics of a person's voice helped pick up lesions in people diagnosed with voice box cancer. 2 The sound of your voice could indicate whether you have signs of cancer Credit: Getty Researchers believe AI could be trained to hear these changes within a "couple of years'. There are around 2,000 new cases of voice box (laryngeal) cancer in the UK each year. A hoarse voice for more than three weeks can be a key symptom, and should be investigated by a GP. Using AI for diagnosis could spell the end of uncomfortable tests currently used, such as a biopsy or nasendoscopy, in which a thin tube with a video camera is passed through the nose down the back of the throat. Read more on cancer HIGH FIVE The 5 simple tweaks you can make TODAY to slash your risk of 5 killer diseases The American team, part of the 'Bridge2AI-Voice' project, gathered voice recordings of 300 patients, some of whom had voice box cancer. They studied at least six features of voice acoustics: the mean fundamental frequency (pitch); jitter, variation in pitch within speech; shimmer, variation of the amplitude; and the harmonic-to-noise ratio. There were "marked" differences between men with and without cancer or a voice box disorder, such as nodules or polyps, specifically the harmonic-to-noise ratio, according to the findings published in the journal Frontiers in Digital Health. It's possible the same will be found for women with a larger dataset. One of the study's authors, Dr Phillip Jenkins, of Oregon Health & Science University, said: "To move from this study to an AI tool that recognises vocal fold lesions, we would train models using an even larger dataset of voice recordings, labelled by professionals. "We then need to test the system to make sure it works equally well for women and men. BBC Gardeners world fans in tears as star reveals terminal cancer diagnosis during show "Voice-based health tools are already being piloted. "I estimate that with larger datasets and clinical validation, similar tools to detect vocal fold lesions might enter pilot testing in the next couple of years." 2 Voice box cancer, or laryngeal cancer, causes voice hoarseness, pain swallowing, or difficulty swallowing, shortness of breath and weight loss Credit: Getty The symptoms of voice box cancer Cancer Research UK have said there are four key symptoms of laryngeal cancer to look out for: 1. Hoarseness or a change in your voice If you have a hoarse voice for more than 3 weeks, it could be a sign of laryngeal cancer, says Cancer Research UK. It's worth seeing a doctor for a full check up and diagnosis, as inflammation of the larynx can also be caused by a cold, a chest infection and overuse of the voice, like singing. 2. Pain or difficulty swallowing If you're experiencing pain or having difficulty swallowing, it might be an indicator something is wrong. Visit your GP if for three weeks or more, you feel: that there is something small stuck in your throat you are struggling to swallow food some pain or a burning sensation when swallowing food that your food is sticking in your throat 3. Shortness of breath Experiencing shortness of breath is a symptom that should trigger an urgent response. Call 999 if you suddenly experience shortness of breath or are struggling to breathe. Some people may also find they have a cough that doesn't go away, they find it difficult to breath or when they inhale it's become noisy (stridor). 4. Weight loss Sudden or dramatic weight loss is a key sign of cancer, including laryngeal. Usually it will happen alongside other symptoms and the body's way of communicating that there is a problem. It may also happen because you're eating less due to pain or because you're having difficulty swallowing. You should see your doctor if you have lost 4 to 5 kg (10lbs) or more in a short time.


Irish Times
07-08-2025
- Irish Times
Eli Lilly obesity pill disappoints in trial, sending shares down 14%
Eli Lilly 's potential obesity pill helped patients lose less weight than investors had hoped during a trial, sending shares in the drugmaker down more than 14 per cent in early trading. The pharmaceutical group said on Thursday that patients taking orforglipron lost an average of 12.4 per cent of their body weight, at the lower end of the market's expectations for the closely watched medicine. Trial participants taking a placebo lost 0.9 per cent. A pill is expected to offer less dramatic weight loss than injectables, where Lilly's Zepbound currently offers the most weight loss at an average of 23 per cent. Evan Seigerman, an analyst at BMO Capital markets, said investors had been hoping for a minimum weight loss of about 13.7 per cent of body weight. Novo Nordisk 's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15 per cent of their body weight. Shares in Novo Nordisk, Lilly's main rival in the obesity market, jumped as much as 14 per cent. Mr Seigerman also said the trial showed the rate of side effects when taking Lilly's pill – nausea, vomiting and diarrhoea – was slightly worse than expected. The trial result was announced as Lilly reported its second-quarter results, beating analysts' expectations, and raised the midpoint of its guidance for the full year. David Ricks, Lilly's chief executive, said it was 'another quarter of strong performance'. The pharmaceutical industry is under pressure from the Trump administration to lower prices voluntarily, or face a 'Most Favoured Nation' drug pricing policy that would peg US drug prices to the lower prices in other developed nations. Mr Ricks warned against importing 'foreign pricing controls', arguing it would harm patients and US competitiveness. The company reported revenues of $15.6 billion (€13.4 billion) in the three months to June, up 38 per cent on the same period last year. Sales of Zepbound, prescribed for obesity, soared by 172 per cent, and Mounjaro, prescribed for diabetes, jumped 68 per cent. Lilly now expects full-year revenue between $60 billion to $62 billion, up from its previous range of $58 billion to $61 billion. The optimistic outlook contrasts sharply with rival Novo Nordisk, which lowered its forecasts for profit and sales growth last week, wiping €60 billion off its value. Novo Nordisk has been losing ground to Lilly in the US market, as well as facing competition from copycat versions of its weight loss and diabetes drugs. Investors had been excited that Lilly could dominate the market for oral weight loss drugs with orforglipron. While the trial result disappointed investors, the once-daily pill met the trial's goals, including showing it can have a positive impact on heart health, and Lilly said it was on track to submit the medicine to regulators for approval later this year. Just over 10 per cent of the high-dose patients dropped out of the Lilly trial due to adverse side effects, the company said. No liver safety issues were seen. In April, Lilly shares jumped almost 15 per cent when another trial, among diabetic patients, showed it could help them lose weight and lower their blood sugar. Daniel Skovronsky, Lilly's chief scientific officer, told analysts they should be wary of comparing trials over different time periods and in different populations. 'Wall Street is kind of focused on the exact numbers here, the cross trial comparisons, [but] I don't think that carries over to the real world,' he said. – Copyright The Financial Times Limited 2025